These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22763826)

  • 1. Effectiveness of basal-supported oral therapy (BOT) using insulin glargine in patients with poorly controlled type 2 diabetes.
    Suzuki D; Umezono T; Miyauchi M; Kimura M; Yamamoto N; Tanaka E; Kuriyama Y; Sato H; Miyatake H; Kondo M; Toyoda M; Fukagawa M
    Tokai J Exp Clin Med; 2012 Jul; 37(2):41-6. PubMed ID: 22763826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
    Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential formula for the calculation of starting and incremental insulin glargine doses: ALOHA subanalysis.
    Kadowaki T; Ohtani T; Naito Y; Odawara M
    PLoS One; 2012; 7(8):e41358. PubMed ID: 22870214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study subanalysis.
    Odawara M; Ohtani T; Kadowaki T
    Diabetes Technol Ther; 2012 Jul; 14(7):635-43. PubMed ID: 22524524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes.
    Suzuki D; Toyoda M; Kondo M; Miyatake H; Tanaka E; Sato H; Kuriyama Y; Miyauchi M; Yamamoto N; Kimura M; Umezono T; Fukagawa M
    Tokai J Exp Clin Med; 2012 Jul; 37(2):35-40. PubMed ID: 22763825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy.
    Takahara M; Shiraiwa T; Kaneto H; Katakami N; Matsuoka TA; Shimomura I
    Endocr J; 2012; 59(12):1131-6. PubMed ID: 22850206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin.
    Takahara M; Shiraiwa T; Katakami N; Matsuoka TA; Shimomura I
    Diabetes Technol Ther; 2014 Oct; 16(10):633-9. PubMed ID: 24949654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA) study.
    Odawara M; Kadowaki T; Naito Y
    J Diabetes Complications; 2015; 29(1):127-33. PubMed ID: 25449981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
    Yki-Järvinen H; Bergenstal R; Ziemen M; Wardecki M; Muehlen-Bartmer I; Boelle E; Riddle MC;
    Diabetes Care; 2014 Dec; 37(12):3235-43. PubMed ID: 25193531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A; Schweitzer MA; Häring HU;
    Ann Intern Med; 2003 Jun; 138(12):952-9. PubMed ID: 12809451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM).
    Janka HU; Hessel F; Walzer S; Mã Ller E
    Int J Clin Pharmacol Ther; 2007 Dec; 45(12):623-30. PubMed ID: 18184530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.
    Moon JS; Ha KS; Yoon JS; Lee HW; Lee HC; Won KC;
    Acta Diabetol; 2014 Apr; 51(2):277-85. PubMed ID: 24445656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA; Baron MA; Gao L; Blonde L
    Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes.
    Tamemoto H; Ikoma A; Saitoh T; Ishikawa SE; Kawakami M
    Diabetes Technol Ther; 2007 Jun; 9(3):246-53. PubMed ID: 17561795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.
    Lee P; Chang A; Blaum C; Vlajnic A; Gao L; Halter J
    J Am Geriatr Soc; 2012 Jan; 60(1):51-9. PubMed ID: 22239291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.